Skip to main content
Vivos Therapeutics, Inc. logo

Vivos Therapeutics, Inc. — Investor Relations & Filings

Ticker · VVOS ISIN · US92859E1082 US Manufacturing
Open in API
Filings indexed 259 across all filing types
Latest filing 2025-12-05 Capital/Financing Update
Country US United States of America
Listing US VVOS

About Vivos Therapeutics, Inc.

https://vivos.com/

Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing diagnostic and treatment methods for sleep-disordered breathing, including obstructive sleep apnea (OSA). The company's core offering is The Vivos System, a non-surgical treatment that uses proprietary oral appliances. These devices are designed to address underlying dentofacial abnormalities that can restrict the airway. The treatment protocol aims to promote the natural growth and development of the jaw and airway in both adult and pediatric patients. Vivos provides its technology and training to a network of licensed dentists and medical professionals who deliver the therapy.

Recent filings

Filing Released Lang Actions
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement involving a Note Purchase Agreement and related financing details. It includes specific terms of the note, payment schedules, and guarantees. There are no comprehensive financial statements or detailed financial analysis typical of annual or interim reports. The document is not a transcript, proxy, or governance report. It is a regulatory filing announcing a financing event and related agreements. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2025-12-05 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce significant events. The text specifically mentions Item 2.02, which is "Results of Operations and Financial Condition," and states that the company issued a press release announcing its financial results for the third quarter ended September 30, 2025. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The length of the document is 4292 characters, which is relatively short and consistent with a current report rather than a full quarterly or annual report. The document is primarily an announcement of financial results rather than the detailed report itself. Therefore, this filing is best classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2025-11-19 English
10-Q
Interim / Quarterly Report Q3 2025
2025-11-19 English
NT 10-Q
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 Notification of Late Filing submitted to the SEC by Vivos Therapeutics, Inc. It specifically states that the company is unable to file its Form 10-Q for the quarter ended September 30, 2025, within the prescribed time period and requests an extension. The document contains no actual financial statements or substantive financial data but explains the reason for the delay and the expected filing date. According to the rules, such a notification is a regulatory filing and not the actual quarterly report (10-Q). Therefore, the correct classification is Regulatory Filings (RNS).
2025-11-14 English
8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated November 4, 2025, by Vivos Therapeutics, Inc. The key content is the submission of matters to a vote of security holders at the company's 2025 annual meeting. It details the election of directors, approval of an amendment to the equity incentive plan, and ratification of the appointment of the independent registered public accounting firm. The document provides detailed voting results for each proposal. This matches the description of a Declaration of Voting Results & Voting Rights Announcements (DVA), which includes official results from shareholder votes at any general meeting (AGM or EGM). The document is not an Annual Report, Audit Report, or Proxy Solicitation, but specifically reports voting outcomes. The length (6345 characters) and detailed vote tabulation confirm it is not a brief announcement but a full voting results report.
2025-11-04 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a registration statement on Form S-3. It updates the maximum amount of shares eligible to be sold under an existing at-the-market offering agreement. The document discusses share issuance and sales details, public float, and market prices, which are typical of capital raising or financing activities. It is not a full financial report, earnings release, or management discussion, but rather an update on financing terms and share issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is under 5,000 characters and contains substantive information about the offering, so it is not merely an announcement or report publication notice.
2025-10-24 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.